The biological basis for this resistance includes tumors that are inherently less immunogenic; they either do not present enough tumor-associated antigens on MHC molecules or fail to attract sufficient cytotoxic T lymphocytes (CTLs) into the tumor microenvironment. The gene discussed is HLA-C; the disease is neoplasm.